Reports
Sale
Primary Sclerosing Cholangitis Market Share, Trends, Report: By Type: Classic PSC, Small-duct PSC, PSC Associated with Autoimmune Hepatitis; By Treatment: Ursodeoxycholic Acid, Obeticholic Acid, Methotrexate, Corticosteroids, Others; By Drug Class: Antihistamines, Cholestyramine, Others; Regional Analysis; Supplier Landscape; 2024-2032
Primary Sclerosing Cholangitis Market Outlook
The primary sclerosing cholangitis market size in the 7 major markets was valued at USD 151.07 million in 2023, driven by the rising technical advancements in drug development. The market is expected to grow at a CAGR of 7.60% during the forecast period of 2024-2032, with the values likely to rise from USD 162.6 million in 2024 to USD 292.1 million by 2032.
Primary Sclerosing Cholangitis: Introduction
Primary sclerosis cholangitis is a chronic liver condition where the bile ducts get inflamed, scarred, and eventually becomes narrow and blocked. The disease progresses slowly and eventually leads to liver failure. Common symptoms include itchy area, abdomen pain, jaundice, diarrhea or fatigue and fever. It is caused by an immune system reaction to a toxin or infection. Liver function blood tests, bile duct MRIs and CT scans are used to diagnose the condition in patients.
Primary Sclerosing Cholangitis Market Analysis
The primary sclerosing cholangitis market demand is poised to rise with increasing frequency of drug development demonstrating positive results in clinical trials. In June 2023, Chemomab Therapeutics Ltd. presented positive data supporting CM-101, a CCL24-neutralizing antibody, as a driver of disease pathology in detecting primary sclerosing cholangitis. In addition, Galmed Pharmaceuticals Ltd. also launched a clinical program to evaluate its lead compound, Aramchol meglumine, for the treatment of PSC. This also indicates the rising trend of pharmaceutical companies taking part in expanding their product portfolios.
As a part of further investigation, researchers have also been working on developing PSC-IBD (inflammatory bowel disease) combined medications. This is because the pathogenesis and treatment for both is similar. Potential candidate drugs, such as those that target modulation of bile acids, inflammation, fibrosis, and gut dysbiosis, have been developed for both. Bile acids modulators such as Obeticholic acid, Cilofexor and inflammation modulators like Cenicriviroc, Vedolizumab, along with statins, are some key areas of investigation. The rising investment and research and development in the market is anticipated to aid the market growth further.
The rising prevalence of minimally invasive procedures, owing to benefits like faster recovery and lesser complications, is expected to boost the primary sclerosing cholangitis market growth in the forecast period.
Primary Sclerosing Cholangitis Market Segmentation
Market Breakup by Type
- Classic PSC
- Small-duct PSC
- PSC Associated with Autoimmune Hepatitis
Market Breakup by Treatment
- Ursodeoxycholic Acid
- Obeticholic Acid
- Methotrexate
- Corticosteroids
- Others
Market Breakup by Drug Type
- Antihistamines
- Cholestyramine
- Antibacterials
- Opioid Antagonists
- Colestipol
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
Primary Sclerosing Cholangitis Market Overview
Owing to the rising primary sclerosing cholangitis market demand, the United States has made significant efforts to offer a diverse of effective treatment alternative to the patients. The presence of prominent pharmaceutical and healthcare companies, as well as research institutions has fuelled the market growth.
To combat the increasing liver associated diseases, countries like Japan, China, and India have been working on improving the medical and research infrastructure of the region. The government of India has launched a ‘Illness to Wellness’ campaign in August 2023. This national awareness program promoted healthy living with balanced diet, along with good eating habits. Such programs are expected to contribute significantly to the rising primary sclerosing cholangitis market share in the coming years.
Europe is another significant player in the market with a well-developed research infrastructure that aids in development and testing of new technologies and drugs. The World Health Organization launched “One life, one liver” to boost awareness on liver health. Such initiatives and campaigns are also anticipated to boost the market value in the forecast period as well.
Primary Sclerosing Cholangitis Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Allergan
- Glenmark Pharmaceutical
- Merck & Co
- Sanofi
- Novatris AG
- Baxter
- Pfizer Inc.
- Takeda Pharmaceutical
- F. Hoffmann-La Roche Ltd
- Abbott
- Mylan N.V.
- HighTide Inc.
- Sirnaomics
- Acorda Therapeutics
- NGM Biopharmaceuticals
- Sandoz International GmbH
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Treatment |
|
| Breakup by Drug Class |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Primary Sclerosing Cholangitis Syndrome Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Primary Sclerosing Cholangitis Epidemiology Analysis – 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Primary Sclerosing Cholangitis Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Primary Sclerosing Cholangitis Epidemiology Forecast (2017-2032)
5.3.1 Germany Primary Sclerosing Cholangitis Epidemiology Forecast (2017-2032)
5.3.2 France Primary Sclerosing Cholangitis Epidemiology Forecast (2017-2032)
5.3.3 Italy Primary Sclerosing Cholangitis Epidemiology Forecast (2017-2032)
5.3.4 Spain Primary Sclerosing Cholangitis Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Primary Sclerosing Cholangitis Epidemiology Forecast (2017-2032)
5.4 Japan Primary Sclerosing Cholangitis Epidemiology Forecast (2017-2032)
6 Primary Sclerosing Cholangitis Market Overview – 7MM
6.1 Primary Sclerosing Cholangitis Market Historical Value (2017-2023)
6.2 Primary Sclerosing Cholangitis Market Forecast Value (2024-2032)
7 Primary Sclerosing Cholangitis Market Landscape – 7MM
7.1 Primary Sclerosing Cholangitis Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Primary Sclerosing Cholangitis Product Landscape
7.2.1 Analysis by Diseases Type
7.2.2 Analysis by Treatments
7.2.3 Analysis by Route of Administration
8 Primary Sclerosing Cholangitis Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Primary Sclerosing Cholangitis Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Primary Sclerosing Cholangitis Market Segmentation – 7MM
11.1 Primary Sclerosing Cholangitis Market by Type
11.1.1 Market Overview
11.1.2 Classic PSC
11.1.3 Small-duct PSC
11.1.4 PSC Associated with Autoimmune Hepatitis
11.2 Primary Sclerosing Cholangitis Market by Treatment
11.2.1 Market Overview
11.2.2 Ursodeoxycholic Acid
11.2.3 Obeticholic Acid
11.2.4 Methotrexate
11.2.5 Corticosteroids
11.2.6 Others
11.3 Primary Sclerosing Cholangitis Market by Drug Class
11.3.1 Market Overview
11.3.2 Antihistamines
11.3.3 Cholestyramine
11.3.4 Antibacterials
11.3.5 Opioid Antagonists
11.3.6 Colestipol
11.3.7 Others
11.4 Primary Sclerosing Cholangitis Market by Region
11.4.1 Market Overview
11.4.2 United States
11.4.3 EU-4 and the United Kingdom
11.4.3.1 Germany
11.4.3.2 France
11.4.3.3 Italy
11.4.3.4 Spain
11.4.3.5 United Kingdom
11.4.4 Japan
12 United States Primary Sclerosing Cholangitis Market
12.1 Primary Sclerosing Cholangitis Market Historical Value (2017-2023)
12.2 Primary Sclerosing Cholangitis Market Forecast Value (2024-2032)
12.3 Primary Sclerosing Cholangitis Market by Disease Type
12.4 Primary Sclerosing Cholangitis Market by Treatment Type
13 EU-4 and United Kingdom Primary Sclerosing Cholangitis Market
13.1 Primary Sclerosing Cholangitis Market Historical Value (2017-2023)
13.2 Primary Sclerosing Cholangitis Market Forecast Value (2024-2032)
13.3 Germany Primary Sclerosing Cholangitis Market Overview
13.3.1 Primary Sclerosing Cholangitis Market by Disease Type
13.3.2 Primary Sclerosing Cholangitis Market by Treatment Type
13.4 France Primary Sclerosing Cholangitis Market Overview
13.4.1 Primary Sclerosing Cholangitis Market by Disease Type
13.4.2 Primary Sclerosing Cholangitis Market by Treatment Type
13.5 Italy Primary Sclerosing Cholangitis Market Overview
13.5.1 Primary Sclerosing Cholangitis Market by Disease Type
13.5.2 Primary Sclerosing Cholangitis Market by Treatment Type
13.6 Spain Primary Sclerosing Cholangitis Market Overview
13.6.1 Primary Sclerosing Cholangitis Market by Disease Type
13.6.2 Primary Sclerosing Cholangitis Market by Treatment Type
13.7 United Kingdom Primary Sclerosing Cholangitis Market Overview
13.7.1 Primary Sclerosing Cholangitis Market by Disease Type
13.7.2 Primary Sclerosing Cholangitis Market by Treatment Type
14 Japan Primary Sclerosing Cholangitis Market
14.1 Primary Sclerosing Cholangitis Market Historical Value (2017-2023)
14.2 Primary Sclerosing Cholangitis Market Forecast Value (2024-2032)
14.3 Primary Sclerosing Cholangitis Market by Disease Type
14.4 Primary Sclerosing Cholangitis Market by Treatment Type
15 Patent Analysis
15.1 Analysis by Type of Patent
15.2 Analysis by Publication year
15.3 Analysis by Issuing Authority
15.4 Analysis by Patent Age
15.5 Analysis by CPC Analysis
15.6 Analysis by Patent Valuation
15.7 Analysis by Key Players
16 Grants Analysis
16.1 Analysis by year
16.2 Analysis by Amount Awarded
16.3 Analysis by Issuing Authority
16.4 Analysis by Grant Application
16.5 Analysis by Funding Institute
16.6 Analysis by NIH Departments
16.7 Analysis by Recipient Organization
17 Clinical Trials Analysis
17.1 Analysis by Trial Registration Year
17.2 Analysis by Trial Status
17.3 Analysis by Trial Phase
17.4 Analysis by Therapeutic Area
17.5 Analysis by Geography
18 Funding Analysis
18.1 Analysis by Funding Instances
18.2 Analysis by Type of Funding
18.3 Analysis by Funding Amount
18.4 Analysis by Leading Players
18.5 Analysis by Leading Investors
18.6 Analysis by Geography
19 Partnership and Collaborations Analysis
19.1 Analysis by Partnership Instances
19.2 Analysis by Type of Partnership
19.3 Analysis by Leading Players
19.4 Analysis by Geography
20 Supplier Landscape
20.1 Allergan
20.1.1 Financial Analysis
20.1.2 Product Portfolio
20.1.3 Demographic Reach and Achievements
20.1.4 Mergers and Acquisition
20.1.5 Certifications
20.2 Glenmark Pharmaceutical
20.2.1 Financial Analysis
20.2.2 Product Portfolio
20.2.3 Demographic Reach and Achievements
20.2.4 Mergers and Acquisition
20.2.5 Certifications
20.3 Merck & Co
20.3.1 Financial Analysis
20.3.2 Product Portfolio
20.3.3 Demographic Reach and Achievements
20.3.4 Mergers and Acquisition
20.3.5 Certifications
20.4 Sanofi
20.4.1 Financial Analysis
20.4.2 Product Portfolio
20.4.3 Demographic Reach and Achievements
20.4.4 Mergers and Acquisition
20.4.5 Certifications
20.5 Novatris AG
20.5.1 Financial Analysis
20.5.2 Product Portfolio
20.5.3 Demographic Reach and Achievements
20.5.4 Mergers and Acquisition
20.5.5 Certifications
20.6 Baxter
20.6.1 Financial Analysis
20.6.2 Product Portfolio
20.6.3 Demographic Reach and Achievements
20.6.4 Mergers and Acquisition
20.6.5 Certifications
20.7 Pfizer Inc.
20.7.1 Financial Analysis
20.7.2 Product Portfolio
20.7.3 Demographic Reach and Achievements
20.7.4 Mergers and Acquisition
20.7.5 Certifications
20.8 Takeda Pharmaceutical
20.8.1 Financial Analysis
20.8.2 Product Portfolio
20.8.3 Demographic Reach and Achievements
20.8.4 Mergers and Acquisition
20.8.5 Certifications
20.9 F. Hoffmann-La Roche Ltd
20.9.1 Financial Analysis
20.9.2 Product Portfolio
20.9.3 Demographic Reach and Achievements
20.9.4 Mergers and Acquisition
20.9.5 Certifications
20.10 Abbott
20.10.1 Financial Analysis
20.10.2 Product Portfolio
20.10.3 Demographic Reach and Achievements
20.10.4 Mergers and Acquisition
20.10.5 Certifications
20.11 Mylan N.V.
20.11.1 Financial Analysis
20.11.2 Product Portfolio
20.11.3 Demographic Reach and Achievements
20.11.4 Mergers and Acquisition
20.11.5 Certifications
20.12 HighTide Inc.
20.12.1 Financial Analysis
20.12.2 Product Portfolio
20.12.3 Demographic Reach and Achievements
20.12.4 Mergers and Acquisition
20.12.5 Certifications
20.13 Sirnaomics
20.13.1 Financial Analysis
20.13.2 Product Portfolio
20.13.3 Demographic Reach and Achievements
20.13.4 Mergers and Acquisition
20.13.5 Certifications
20.14 Acorda Therapeutics
20.14.1 Financial Analysis
20.14.2 Product Portfolio
20.14.3 Demographic Reach and Achievements
20.14.4 Mergers and Acquisition
20.14.5 Certifications
20.15 NGM Biopharmaceuticals
20.15.1 Financial Analysis
20.15.2 Product Portfolio
20.15.3 Demographic Reach and Achievements
20.15.4 Mergers and Acquisition
20.15.5 Certifications
20.16 Sandoz International GmbH
20.16.1 Financial Analysis
20.16.2 Product Portfolio
20.16.3 Demographic Reach and Achievements
20.16.4 Mergers and Acquisition
20.16.5 Certifications
21 Primary Sclerosing Cholangitis Market - Distribution Model (Additional Insight)
21.1 Overview
21.2 Potential Distributors
21.3 Key Parameters for Distribution Partner Assessment
22 Key Opinion Leaders (KOL) Insights (Additional Insight)
23 Company Competitiveness Analysis (Additional Insight)
23.1 Very Small Companies
23.2 Small Companies
23.3 Mid-Sized Companies
23.4 Large Companies
23.5 Very Large Companies
24 Payment Methods (Additional Insight)
24.1 Government Funded
24.2 Private Insurance
24.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 151.07 million in 2023 in the 7 major markets, driven by the rising technical advancements in drug development.
The market is anticipated to grow at a CAGR of 7.60% during the forecast period of 2024-2032, likely to reach a market value of USD 292.1 million by 2032.
The market demand is driven by rising prevalence of primary sclerosing cholangitis due to unhealthy dietary habits and increased alcohol consumption, impacting the liver poorly.
The major market trends include the rising incidence of clinical trials to offer new treatment solutions to the patients affected by the disease.
Based on type, the market is divided into classic PSC, small-duct PSC, and PSC associated with autoimmune hepatitis.
The available treatments in the market include Ursodeoxycholic Acid, Obeticholic Acid, Methotrexate, and corticosteroids, among others.
The drug class can be categorised into antihistamines, cholestyramine, antibacterials, opioid antagonists, and colestipol, among others.
What are the major regional markets for primary sclerosing cholangitis, according to the EMR report?
The major regions of the market include the United States, Japan, EU-4 and the United Kingdom. EU-4 is segmented into Germany, France, Italy, and Spain.
Key players involved in the market are Allergan, Glenmark Pharmaceutical, Merck & Co, Sanofi, Novartis AG, Baxter, Pfizer Inc., Takeda Pharmaceutical, F. Hoffmann-La Roche Ltd., Abbott, Mylan N.V., HighTide Inc., Sirnaomics, Acorda Therapeutics, NGM Biopharmaceuticals, and Sandoz International GmbH.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER